Plasma concentrations of 5-fluorouracil and F-β-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protra...

por Yamada, Y, Hamaguchi, T, Goto, M, Muro, K, Matsumura, Y, Shimada, Y, Shirao, K, Nagayama, S
Publicado 2003

Phase I clinical trial and pharmacokinetic evaluation of NK911, a micelle-encapsulated doxorubicin

por Matsumura, Y, Hamaguchi, T, Ura, T, Muro, K, Yamada, Y, Shimada, Y, Shirao, K, Okusaka, T, Ueno, H, Ikeda, M, Watanabe, N
Publicado 2004

BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer

por Yokota, T, Ura, T, Shibata, N, Takahari, D, Shitara, K, Nomura, M, Kondo, C, Mizota, A, Utsunomiya, S, Muro, K, Yatabe, Y
Publicado 2011

A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation

por Hamaguchi, T, Kato, K, Yasui, H, Morizane, C, Ikeda, M, Ueno, H, Muro, K, Yamada, Y, Okusaka, T, Shirao, K, Shimada, Y, Nakahama, H, Matsumura, Y
Publicado 2007

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer

por Koizumi, W, Yamaguchi, K, Hosaka, H, Takinishi, Y, Nakayama, N, Hara, T, Muro, K, Baba, H, Sasaki, Y, Nishina, T, Fuse, N, Esaki, T, Takagi, M, Gotoh, M, Sasaki, T
Publicado 2013

Randomised phase II study of S-1/cisplatin plus TSU-68 vs S-1/cisplatin in patients with advanced gastric cancer

por Koizumi, W, Yamaguchi, K, Hosaka, H, Takinishi, Y, Nakayama, N, Hara, T, Muro, K, Baba, H, Sasaki, Y, Nishina, T, Fuse, N, Esaki, T, Takagi, M, Gotoh, M, Sasaki, T
Publicado 2014

Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer

por Kato, K., Masuishi, T., Fushiki, K., Nakano, S., Kawamoto, Y., Narita, Y., Tsushima, T., Harada, K., Kadowaki, S., Todaka, A., Yuki, S., Tajika, M., Machida, N., Komatsu, Y., Yasui, H., Muro, K., Kawakami, T.
Publicado 2021

Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer

por Shitara, K, Yuki, S, Tahahari, D, Nakamura, M, Kondo, C, Tsuda, T, Kii, T, Tsuji, Y, Utsunomiya, S, Ichikawa, D, Hosokawa, A, Ishiguro, A, Sakai, D, Hironaka, S, Oze, I, Matsuo, K, Muro, K
Publicado 2014

A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR)

por Okamoto, W., Sakai, K., Makiyama, A., Yamamoto, Y., Shitara, K., Denda, T., Izawa, N., Nakano, Y., Nishina, T., Esaki, T., Hara, H., Miura, Y., Boku, N., Yamazaki, K., Hironaka, S., Misumi, T., Hyodo, I., Muro, K., Nishio, K.
Publicado 2022

Quality-of-life and performance status results from the phase III RAINBOW study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated ga...

por Al-Batran, S.-E., Van Cutsem, E., Oh, S. C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O. N., Kim, T.-Y., Cunningham, D., Rougier, P., Muro, K., Liepa, A. M., Chandrawansa, K., Emig, M., Ohtsu, A., Wilke, H.
Publicado 2016

Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study

por Tabernero, J, Hozak, R R, Yoshino, T, Cohn, A L, Obermannova, R, Bodoky, G, Garcia-Carbonero, R, Ciuleanu, T -E, Portnoy, D C, Prausová, J, Muro, K, Siegel, R W, Konrad, R J, Ouyang, H, Melemed, S A, Ferry, D, Nasroulah, F, Van Cutsem, E
Publicado 2018

Biomarker analysis beyond angiogenesis: RAS/RAF mutation status, tumour sidedness, and second-line ramucirumab efficacy in patients with metastatic colorectal carcinoma from RAISE—...

por Yoshino, T, Portnoy, D C, Obermannová, R, Bodoky, G, Prausová, J, Garcia-Carbonero, R, Ciuleanu, T, García-Alfonso, P, Cohn, A L, Van Cutsem, E, Yamazaki, K, Lonardi, S, Muro, K, Kim, T W, Yamaguchi, K, Grothey, A, O’Connor, J, Taieb, J, Wijayawardana, S R, Hozak, R R, Nasroulah, F, Tabernero, J
Publicado 2019

Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials

por Yoshino, T., Cleary, J. M., Van Cutsem, E., Mayer, R. J., Ohtsu, A., Shinozaki, E., Falcone, A., Yamazaki, K., Nishina, T., Garcia-Carbonero, R., Komatsu, Y., Baba, H., Argilés, G., Tsuji, A., Sobrero, A., Yamaguchi, K., Peeters, M., Muro, K., Zaniboni, A., Sugimoto, N., Shimada, Y., Tsuji, Y., Hochster, H. S., Moriwaki, T., Tran, B., Esaki, T., Hamada, C., Tanase, T., Benedetti, F., Makris, L., Yamashita, F., Lenz, H.-J.
Publicado 2020

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 24th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2022

por Ducreux, M., Abou-Alfa, G.K., Bekaii-Saab, T., Berlin, J., Cervantes, A., de Baere, T., Eng, C., Galle, P., Gill, S., Gruenberger, T., Haustermans, K., Lamarca, A., Laurent-Puig, P., Llovet, J.M., Lordick, F., Macarulla, T., Mukherji, D., Muro, K., Obermannova, R., O’Connor, J.-M., O’Reilly, E.M., Osterlund, P., Philip, P., Prager, G., Ruiz-Garcia, E., Sangro, B., Seufferlein, T., Tabernero, J., Verslype, C., Wasan, H., Van Cutsem, E.
Publicado 2023